No Data
What CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 37% Share Price Gain Is Not Telling You
There are currently no expansion plans for the Active Pharmaceutical Ingredient Business. CSPC Innovation Pharmaceutical is expected to receive the first installment of the BD payment in the first half of this year | Focus on the Earnings Conference.
① In the future, CSPC Innovation Pharmaceutical will continue to explore SYS6010 (EGFR ADC) for indications such as gastrointestinal cancer. ② CSPC Innovation Pharmaceutical has reviewed the progress of its GLP-1 products, stating that some MNCs have already expressed interest in the company's related varieties. ③ The Active Pharmaceutical Ingredient business is currently focused on cost reduction through process technology upgrades, with no plans for expansion at this time.
CSPC Innovation Pharmaceutical (300765.SZ): The controlling subsidiary SYS6040 antibody-drug conjugate has received a notice of approval for clinical trials.
On March 21, Glonghui reported that CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary, CSPC PHARMA Giant Stone Biological Pharmaceutical Co., Ltd. (referred to as "Giant Stone Bio"), recently received the Clinical Trial Approval Notice for the antibody-drug conjugate SYS6040 issued by the National Medical Products Administration. Clinical trials will be conducted in the near future. SYS6040 is a monoclonal antibody-conjugated drug that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins to kill tumor cells. This product is declared as a Class 1 Biological Product for therapeutic use.
CSPC Innovation Pharmaceutical 2024 Profit Falls 88%; Shares Down 6%
New Novus: 2024 Annual Report
New Novus: 2024 Annual Report Summary